Article thumbnail

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

By Christian Tovar, Brian Higgins, Kenneth Kolinsky, Mingxuan Xia, Kathryn Packman, David C Heimbrook and Lyubomir T Vassilev
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3094321
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2004). A: Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate
  2. (1995). A: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.
  3. (2005). A: Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate
  4. (2005). AJ: MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets
  5. (2000). AJ: Surfing the p53 network. Nature
  6. (1993). AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev
  7. (2002). An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opin Pharmacother
  8. (2006). Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene
  9. (2009). Balk SP: Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol
  10. (2004). Bicalutamide (Casodex) in the treatment of prostate cancer. Expert Rev Anticancer Ther
  11. (2008). CC: Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res
  12. (2007). Choubey D: Expression of androgen receptor is negatively regulated by p53. Neoplasia
  13. (2006). CJ: The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
  14. (2005). Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA
  15. (2003). deVere White RW: Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res
  16. (2009). DP: Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer
  17. (1992). E: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.
  18. (2000). et al: Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
  19. (2004). et al: Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res
  20. (1997). et al: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgendependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol
  21. (2004). et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science
  22. (2006). et al: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA
  23. (2001). Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer
  24. (1941). HC: Studies on prostate cancer. 1. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res
  25. (2001). Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet
  26. (2004). Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene
  27. (1988). Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology
  28. (2009). Isaacs JT: Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate
  29. (2000). KR: Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res
  30. (2001). L: p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction.
  31. (2005). Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene
  32. (2005). MB: Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene
  33. (2008). MB: MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther
  34. (2010). NA: Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol
  35. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett
  36. (2002). Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require
  37. (1998). Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res
  38. (1999). Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence.
  39. (1986). Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods
  40. (2003). RL: LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate
  41. (2001). Sausville EA: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
  42. (1997). SC: Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal-stripped media. Prostate
  43. (1999). SP: Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res
  44. (2006). Tindall DJ: Molecular regulation of androgen action in prostate cancer.
  45. (2008). Vassilev LT: Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle
  46. (2006). Weigel NL: Androgen receptor action in hormonedependent and recurrent prostate cancer.